Science & Technology
Space Station to Host Advanced Biomedical Research via SpaceX CRS-35 Mission
The next commercial resupply mission to the International Space Station, SpaceX CRS-35, will carry a suite of biomedical investigations aimed at understanding and mitigating health risks associated with spaceflight. Key experiments include using organ-on-a-chip technology to study bone loss (MABL-A), investigating cartilage degeneration that mimics osteoarthritis (MVP-Cell-06), and examining how microgravity affects heart muscle cells (STEM-C). These studies leverage the unique microgravity environment to accelerate disease modeling and test potential treatments that could benefit both astronauts on long-duration missions and patients on Earth.
By Obvious Later Editorial · Updated
Published
Updated
Access
Evidence strength
Time horizon
Impact
Evidence
What changed
NASA is launching the SpaceX CRS-35 mission, which includes a new set of sophisticated biomedical experiments for the International Space Station. These investigations will utilize advanced tools like organ-on-a-chip platforms to study the molecular and cellular mechanisms behind spaceflight-induced health issues such as bone loss, cartilage degradation, and cardiac dysfunction.
Why it matters
This research is crucial for enabling long-duration human spaceflight by developing countermeasures against the negative health effects of microgravity. Furthermore, by using microgravity to accelerate the progression of Earth-based diseases like osteoporosis and osteoarthritis, these experiments could lead to faster development and testing of new therapies for the general population.
The surprising part
Beyond being a routine resupply run, this mission represents a significant step in using the ISS as a sophisticated biomedical laboratory. The use of advanced platforms like organs-on-chips allows for more complex and human-relevant disease modeling in space than was previously possible, bridging the gap between fundamental space biology and translational medicine for Earth.
Key facts
- The SpaceX CRS-35 mission is a Commercial Resupply Services flight for NASA to the International Space Station.
- The mission will launch from NASA’s Kennedy Space Center in Florida.
- One investigation, MABL-A, uses an organ-on-a-chip platform to study microgravity-associated bone loss.
- The MVP-Cell-06 experiment investigates cartilage degeneration in microgravity as a model for post-traumatic osteoarthritis.
- The STEM-C study examines the effects of microgravity on stem cell-derived cardiomyocytes (heart muscle cells).
What to watch next
How we'll know if this is real.
Next
The published results from the MABL-A, MVP-Cell-06, and STEM-C experiments, which will detail the cellular and molecular changes observed.
Next
Announcements of any new potential drug candidates or therapeutic strategies identified through these ISS-based studies.
Next
How these findings are incorporated into health protocols for future long-duration missions, including NASA's Artemis program.
Evidence and sources
Citations link to the primary sources used to compile this signal.